Aimmune Therapeutics (NASDAQ:AIMT) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

Several other brokerages have also recently issued reports on AIMT. Roth Capital initiated coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Wedbush restated an “ourperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, August 14th. Credit Suisse Group upped their target price on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $49.40.

Shares of Aimmune Therapeutics (NASDAQ AIMT) traded down $0.18 during trading on Friday, hitting $38.02. 328,179 shares of the stock traded hands, compared to its average volume of 364,041. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09. sell-side analysts expect that Aimmune Therapeutics will post -2.57 earnings per share for the current year.

In related news, insider Susan E. Barrowcliffe sold 18,390 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total value of $404,580.00. Following the completion of the sale, the insider now owns 3,223 shares in the company, valued at approximately $70,906. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mary M. Rozenman sold 30,000 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $22.50, for a total transaction of $675,000.00. Following the completion of the sale, the insider now owns 30,129 shares of the company’s stock, valued at approximately $677,902.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 317,720 shares of company stock valued at $8,400,244. 24.56% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares during the last quarter. Legal & General Group Plc raised its position in Aimmune Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC raised its position in Aimmune Therapeutics by 31.2% during the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after buying an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Aimmune Therapeutics during the 2nd quarter worth $333,000. Finally, Citadel Advisors LLC purchased a new position in Aimmune Therapeutics during the 2nd quarter worth $360,000. Hedge funds and other institutional investors own 73.38% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/03/aimmune-therapeutics-aimt-rating-lowered-to-sell-at-valuengine.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.